Preliminary Program (7/1/2013)

Vaccine Delivery and Stabilization: Improving the Reach of Vaccines

September 8 – 10, 2013
Boston, Massachusetts, USA

Co-Chairs:

Robert K. Evans
Merck & Co., USA

Mark A.F. Kendall
University of Queensland, Australia
Sunday, September 8, 2013

16:00 – 18:00  Conference Check-in
18:00 – 18:30  Welcome remarks and Introduction
18:30 – 19:30  Keynote Speaker: Vaccines of the Future: Innovating Beyond the Antigen
Dr. Julie Gerberding, SVP, Global Marketing, Vaccines, Merck
19:30 – 20:15  Reception
20:15 – 22:00  Dinner
Monday, September 9, 2013

08:00 – 09:00  Breakfast
09:00 – 09:30  Opening remarks and Conference Session kickoff

Session 1: Delivery Technologies & Devices
Session Chair: Mark Prausnitz, Georgia Institute of Technology, USA

09:30 – 10:00  Intradermal delivery and dose-sparing: vaccine-specific issues
                Julian Hickling, Working in Tandem, Ltd., United Kingdom

10:00 – 10:30  Rational design of microprojection array-mediated vaccine delivery to skin,
                using mathematical modelling and experimental methods
                Stefano Meliga, Australian Institute for Bioengineering and Nanotechnology, Australia

10:30 – 11:00  Coffee break

11:00 – 11:30  History, recent data, and promise for cutaneous vaccination against influenza
                Bruce Weniger, Chiang Mai University, USA

11:30 – 12:00  Dermal polio vaccination using novel hollow microneedle technology
                Wim Jiskoot, University of Leiden, Netherlands

12:00 – 13:30  Lunch

Session 2: Mechanisms: Mode of Action
Session Chair: Bruce Weniger, Chiang Mai University, USA

13:30 – 14:00  Enhanced systemic immunogenicity achieved by co-localising vaccine with
                nanopatch-mediated skin damage adjacent to live cells
                Alexandra Depelsenaire, Australian Institute for Bioengineering and Nanotechnology, Australia

14:00 – 14:30  TBA
                Andrew Geall, Novartis, USA

14:30 – 15:00  The resident memory T-cell concept and vaccination: can we manipulate the system?
                David Koelle, University of Washington, USA

15:00 – 15:15  Stretch break

15:15 – 15:45  In vivo active delivery of antigens with dendritic cell-targeting bio-nanocapsules
                Hidenori Matsuo, Nagoya University, Japan

15:45 – 16:15  In vitro modeling of Age-Specific Immunity to Inform Vaccine Development
                Ofer Levy, Harvard Medical School, USA

16:15 – 16:45  Coffee break
Monday, September 9, 2013 (continued)

Session 3: Adjuvants: Formulations & Mechanisms:
Session Chair: Danny Casimiro, Merck & Co., USA

16:45 – 17:15  TBA
Steve Reed, Infectious Disease Research Institute, USA

17:15 – 17:45  The next generation of vaccine adjuvants
Derek O’Hagen, Novartis, USA

17:45 – 18:15  Formulation, Stability and Immunogenicity of Protein-Based Vaccines in Aluminum Salt Adjuvants
S. Fernando Ausar, Sanofi Pasteur, Canada

18:15 – 18:45  Safety issues associated with vaccine administration
Neal Halsey, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health

19:00- 19:30  Reception

19:30 – 21:00  Conference Banquet
Tuesday, September 10, 2013

08:00 – 09:00  Breakfast

Session 4: Novel Stabilization Approaches & Formulations
Session Chair: TBA

09:00 – 09:15  Opening remarks

09:15 – 09:45  Vaccines as Well-Defined Pharmaceutical Dosage Forms: Formulation and Analytical Challenges and Opportunities
David Volkin, University of Kansas, USA

09:45 – 10:15  Developing Thermostable Vaccines for Global Health-Lessons Learned
Dexiang Chen, PATH, USA

10:15 – 10:45  The effect of protein oxidation on the formation of higher order structures and loss of potency for a recombinant influenza hemagglutinin
Kathy Holtz, Protein Sciences Corporation, USA

10:45 – 11:15  Coffee break

11:15 – 11:45  High-throughput screening of microneedle formulations for influenza vaccine stabilization
Matt Mistilis, Georgia Institute of Technology, USA

11:45 – 12:15  Conformational stabilization of vaccine immunogens by targeted di-tyr crosslinking
Christopher Marshall, Avatar Biotechnologies, USA

12:15 – 12:45  Silk stabilization of vaccines: a new route to improving access
Kathryn Kosuda, Vaxess Technologies, Inc., USA

12:45 – 14:15  Lunch

Session 5: Innovations & New Technologies for Reaching the Developing World
Session Chair: Davinder Gil, Hilleman Laboratories, India

14:15 – 14:45  TBA
Penny Heaton, Bill & Melinda Gates Foundation, USA

14:45 – 15:15  TBA
Darin Zehrung, PATH, USA

15:15 – 15:45  Optimization of Rotavirus Vaccine for Developing World
Sachin Kale, Hilleman Laboratories, India

15:45 – 16:15  Thermostable, needle-free influenza vaccines formulated in Bionedules
Gideon Kersten, Institute for Translational Vaccinology, Netherlands

16:15 – 16:30  Closing remarks